Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block. Comment on Br J Anaesth 2024; 132: 45-52

Br J Anaesth. 2024 Apr;132(4):820-821. doi: 10.1016/j.bja.2024.01.009. Epub 2024 Jan 30.

Authors

Yusuke Miyazaki¹, Kaoru Suzuki¹, Hiroshi Sunaga²

Affiliations

¹ Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan.
² Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan. Electronic address: hs-031@jikei.ac.jp.

PMID: 38296751
DOI: 10.1016/j.bja.2024.01.009

No abstract available

Keywords: adamgammadex; adverse drug reaction; anaphylaxis; recurarisation; sugammadex.

Publication types

Clinical Trial, Phase III
Letter

MeSH terms

Androstanols / pharmacology
Humans
Neuromuscular Blockade*
Neuromuscular Nondepolarizing Agents*
Rocuronium
Sugammadex / pharmacology
gamma-Cyclodextrins* / pharmacology

Substances

Sugammadex
Rocuronium
gamma-Cyclodextrins
Neuromuscular Nondepolarizing Agents
Androstanols